Welcome to the 5th Annual Genome Editing Therapeutics Summit

Only 11 years after Emmanuelle Charpentier and Jennifer Doudna’s seminal paper, Casgevy marks the remarkable first approval of a gene editing therapy, a landmark moment for a still-developing field. Following closely is a growing pipeline of precision genome editing techniques that are beginning to revolutionize the treatment of genetic diseases. 

The 5th Genome Editing Therapeutics Summit (formerly CRISPR 2.0) is the industry’s foremost meeting for spearheading the development, application, and delivery of novel gene editing technologies in the therapeutic setting. Data-driven talks, expert panel discussions, and interactive group discussions will cover the therapeutic application and drug development challenges of both:

More established technologies, and their associated translational, nonclinical, clinical, and strategic challenges: including novel nucleases, base, prime, and multiplex editing techniques

Ground-breaking precision tools enabling small and large alterations to the genome, including epigenome editing, recombinase and transposon-based technologies, and novel delivery vehicles

Across three days, industry and academic leaders will share the latest data on the cutting-edge therapies they are progressing through development, tying in the strategies they are deploying to ensure their safety, precision, and regulatory compliance.  

This is the industry’s only gene editing meeting that prioritizes drug development first, with a particular focus on robust safety packages, off-target detection, and nomination strategies; facilitating successful IND filings. Leverage actionable insights to improve the precision and safety of your technology, unlock the ability to perform small and large targeted edits, and outline a streamlined path to clinic for your lead program. 

Join us to be a part of the gene editing revolution.